PDCD1 and neoplasm: Our work supports the notion that the efficacy of anti-PD-1 therapy is limited by an inability to adequately activate immune effector cell populations to mount anti-tumor immunity due to the effects of metabolic alterations in platinum-resistant NSCLC.